Raid Aljumaily to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Raid Aljumaily has written about Antineoplastic Agents, Immunological.
Connection Strength
1.406
-
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. Am J Ther. 2018 Nov/Dec; 25(6):e767-e768.
Score: 0.601
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
Score: 0.177
-
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 2021 05; 155:151-155.
Score: 0.177
-
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.
Score: 0.160
-
Harnessing the PD-1 Pathway in Myelodysplastic Syndrome. Am J Ther. 2018 Nov/Dec; 25(6):e711-e712.
Score: 0.150
-
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018 01; 19(1):51-64.
Score: 0.141